Retatrutide is an investigational triple-hormone receptor agonist designed to aid in weight management and glucose control. It simultaneously targets the GLP-1 (Glucagon-Like Peptide-1), GIP (Glucose-Dependent Insulinotropic Polypeptide), and glucagon receptors, contributing to significant weight loss and improved metabolic health.
UPA - Retatrutide 30mg Pen - 8 Weeks
Key Points:
Mechanism of Action: Activates GLP-1, GIP, and glucagon receptors to enhance insulin secretion, improve glucose metabolism, and promote weight loss.
Clinical Trials: In a 48-week phase 2 study, participants with obesity experienced substantial weight reductions of up to 24.2% with higher doses of Retatrutide.
Dosage Recommendations
Week 1-4: Dose 2.5mg - 25 Units on the pen
Week 5-8: Dose 5mg - 50 Units on the pen
Week 9-12: Dose 7.5mg - 75 Units on the pen
Week 13-16: Dose 10mg - 100 Units on the pen
Week 17-20: Dose 12.5mg - 125 Units on the pen
